Pfizer and BioNTech Submit Data on Vaccine for Kids 5 to 11
The companies said that their vaccine was safe and effective in that age group, and that they would submit a formal request in the coming weeks to U.S. regulators to allow a pediatric dose.
View original article
Contributor: Sharon LaFraniere, Shashank Bengali and Noah Weiland
